Clinical Trial Update: SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) [Phase 1]

View source ↗

Summary

This is a Phase 1 trial evaluating SL-401 (tagraxofusp) in combination with azacitidine or azacitidine plus venetoclax for acute myeloid leukemia, high-risk mye…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Blastic Plasmacytoid Dendritic Cell Neoplasm
• Myelodysplastic Syndrome

Drugs mentioned

• Tagraxofusp (SL-401) (tagraxofusp)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 1 | Status: RECRUITING